

Smarter Triage for Colonoscopy Referrals

ColoSTAT[®] is a blood test that aids colorectal cancer (CRC) diagnosis in symptomatic patients.

It works by measuring blood-based protein biomarkers to determine the likelihood of a patient having colorectal cancer.

ColoSTAT[®] has been validated across multiple populations, with data supporting its ability to detect early-stage colorectal cancers with high accuracy, and over 90% sensitivity.

Developed by Rhythm Biosciences, from innovative CSIRO research, it allows you to triage smarter, prioritising patients most likely to have CRC and reducing colonoscopy wait lists.

COLOSTAT[®]
Colorectal Cancer Test

Why use ColoSTAT[®]

- ✓ **High sensitivity:** ColoSTAT[®] has a sensitivity of 91% for early stage colon cancer; 58 % for advanced adenomas and 99.4 % NPV¹
- ✓ **Protect capacity:** Reduce unnecessary scopes, freeing your time for high-risk cases
- ✓ **Meet ACSQH standards:** Only 15% of Category 1 colonoscopies are performed within the national guideline of 30 days²
- ✓ **Catch missed cases:** Identifies CRC in FIT-negative but symptomatic patients
- ✓ **Complement FIT:** CRC-specific detection improves risk stratification



Intended use claim

ColoSTAT[®] is a qualitative multiplex immunoassay that utilises the detection of protein biomarkers in human serum to aid the diagnosis of colorectal cancer.

It is intended for individuals with symptoms associated with Colorectal Cancer (CRC). A positive result may indicate the presence of colorectal neoplasia and should be followed up with a colonoscopy.

ColoSTAT[®] is not a replacement for colonoscopy.

Perfect for low risk patients


- ✓ aged 45-84
- ✓ with symptoms of bowel cancer
- ✓ reluctant to do stool-based tests

Find out more about how ColoSTAT[®] can support you to quickly and effectively triage patients with symptoms of CRC by emailing support@rhythmbio.com or visiting www.rhythmbio.com.

COLOSTAT[®]
Colorectal Cancer Test

RHYTHM[™]
BIOSCIENCES

ColoSTAT[®] performance¹



ColoSTAT [®] Sensitivity (%) at each Cancer Stage				
I	II	III	IV	Advanced Adenomas
85.0%	95.7%	84.4%	100.0%	58.0%

Internal data, Rhythm Biosciences 2025

Testing process

Rhythm Biosciences works with 4Cyte Pathology to collect and send patient samples to our NATA-accredited facility.

A list of collection facilities are available at colostat.com.

Early detection saves lives

About Rhythm Biosciences and ColoSTAT[®]

Rhythm Biosciences is an Australian diagnostics company focused on developing simple, affordable and accurate tests for the early detection of cancers.

Rhythm Biosciences developed ColoSTAT[®] from innovative CSIRO research.

ColoSTAT[®] simplifies the process for CRC and may help reduce morbidity and mortality rates.

Learn how ColoSTAT[®] may help you triage possible CRC patients more efficiently at rhythmbio.com.

Ask your GP colleagues about integrating ColoSTAT[®] into their referral workflow.

References

1. Internal data, Rhythm Biosciences 2025
2. AIHW, National Bowel Cancer Screening Program monitoring report 2025



AU-HCP-COLOSTAT-2-3

Find out more about how ColoSTAT[®] can support you to quickly and effectively triage patients with symptoms of CRC by emailing support@rhythmbio.com or visiting www.rhythmbio.com.

COLOSTAT[®]
Colorectal Cancer Test

RHYTHM[™]
BIOSCIENCES